We are live on ! Find out more
CABA icon

Cabaletta Bio

75 hedge funds and large institutions have $162M invested in Cabaletta Bio in 2025 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 24 increasing their positions, 31 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

5,676% more call options, than puts

Call options by funds: $5.26M | Put options by funds: $91K

46% more capital invested

Capital invested by funds: $111M → $162M (+$51.3M)

13% less funds holding

Funds holding: 8675 (-11)

23% less repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 31

52% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 21

67.73% less ownership

Funds ownership: 143.4%75.67% (-68%)

Holders
75
Holders Change
-11
Holders Change %
-12.79%
% of All Funds
0.98%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
10
Increased
24
Reduced
31
Closed
21
Calls
$5.26M
Puts
$91K
Net Calls
+$5.17M
Net Calls Change
+$3.51M
Name Holding Trade Value Shares
Change
Change in
Stake
Jones Financial Companies
51
Jones Financial Companies
Missouri
$47.2K +$34.3K +20,007 New
CFS
52
CRA Financial Services
New Jersey
$35.1K +$6.86K +4,000 +36%
Fidelity Investments
53
Fidelity Investments
Massachusetts
$32.9K -$2.39K -1,392 -9%
Manulife (Manufacturers Life Insurance)
54
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$30.6K -$45.8K -26,686 -67%
American Century Companies
55
American Century Companies
Missouri
$28.2K +$20.6K +12,032 New
Squarepoint
56
Squarepoint
New York
$27.8K -$102K -59,573 -83%
RC
57
Rangeley Capital
Connecticut
$26.4K -$8.06K -4,700 -29%
CIAM
58
Caitong International Asset Management
Hong Kong
$21K +$15.4K +8,983 New
PAS
59
Point72 Asia (Singapore)
Singapore
$20.9K -$44.3K -25,832 -74%
TRCT
60
Tower Research Capital (TRC)
New York
$10.2K -$80.1K -46,669 -91%
Barclays
61
Barclays
United Kingdom
$7.21K -$11.4K -6,654 -68%
Wells Fargo
62
Wells Fargo
California
$7.02K -$6.32K -3,686 -55%
BNP Paribas Financial Markets
63
BNP Paribas Financial Markets
France
$4.29K -$81K -47,235 -96%
RA
64
Rise Advisors
New York
$2.53K
Russell Investments Group
65
Russell Investments Group
United Kingdom
$2.2K
Nisa Investment Advisors
66
Nisa Investment Advisors
Missouri
$1.9K -$173 -101 -11%
TC
67
Truvestments Capital
Florida
$1.59K -$2.22K -1,293 -66%
PNC Financial Services Group
68
PNC Financial Services Group
Pennsylvania
$1.4K -$1.22K -709 -54%
SS
69
SBI Securities
Japan
$1.07K -$10.4K -6,060 -93%
Citigroup
70
Citigroup
New York
$824 -$107K -62,147 -99%
FDCDDQ
71
Federation des caisses Desjardins du Quebec
Quebec, Canada
$796
Optiver Holding
72
Optiver Holding
Netherlands
$56 +$41 +24 New
AAP
73
Arax Advisory Partners
Colorado
$23 +$17 +10 New
Northwestern Mutual Wealth Management
74
Northwestern Mutual Wealth Management
Wisconsin
$5 +$3 +2 New
AFM
75
Anson Funds Management
Texas
-$2.77M -1,822,830 Closed

CABA Hedge Fund Activity: Q3 2025 in Review

75 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Cabaletta Bio (CABA) for Q3 2025, worth a combined $162M — up 46% from $111M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of CABA and 10 opened new positions — a net loss of 11 holders — while 31 trimmed existing stakes and 24 added.

The largest buyer was Jennison Associates, adding an estimated $4.25M. The largest seller was Alyeska Investment Group, cutting an estimated $6.01M.

  • 75 institutional investors held Cabaletta Bio (CABA) as of Q3 2025, down from 86 in Q2 2025.
  • Funds reported $162M of Cabaletta Bio stock for Q3 2025, up 46% quarter-over-quarter.
  • 10 funds opened new Cabaletta Bio positions in Q3 2025 and 21 closed out, a net change of -11 holders.
  • The largest Cabaletta Bio buyer in Q3 2025 was Jennison Associates, an estimated $4.25M added.
  • The largest Cabaletta Bio seller in Q3 2025 was Alyeska Investment Group, an estimated $6.01M sold.

Based on aggregated 13F filings for Q3 2025.